Insights
Evidence-based analysis and guidelines for physicians, researchers, care teams, and people living with obesity on AOM treatments.
-
Clinical Research & Preprint
What should we ask patients living with obesity every week? Towards a phenotype-informed framework
Between quarterly consultations, obesity operates continuously. Why we need a continuous, weekly patient-reported framework informed by phenotypes, and our open-access preprint on Zenodo.
-
Access to care
Wegovy and Mounjaro reimbursed in France: conditions, dates, prescription
65% by French National Health Insurance from 15 June 2026. Eligibility criteria (BMI, comorbidities, 6-month nutritional management failure), specialist prescription, cost, out-of-pocket amount – and what this changes for patients outside reimbursement.
-
Side effects
GLP-1 side effects, month by month: what is normal, what is not
A structured timeline of the side effects most commonly reported on GLP-1 therapies, what to expect at each dose step, and the red flags that warrant a call to your physician.
-
Adherence
Why half of GLP-1 patients stop in the first year, and what changes the trajectory
The real-world evidence on persistence, the four reasons people give up, and what the literature says about staying the course on anti-obesity medication.
-
Nutrition
Eating on GLP-1 without counting: a calmer way
Why calorie tracking is the wrong tool on AOMs, what to focus on instead (rhythm, satiety, protein, fibre), and how to handle the appetite-flat days without panic.
-
Plateau & rebound
Plateau and rebound on AOM: what the evidence actually says
Why weight stalls happen, when they are normal, when to discuss titration with your physician, and what the data shows on rebound after dose changes.
-
Mental load
The mental load of being on an anti-obesity medication
The invisible work of explaining your treatment, dealing with stigma, managing identity shifts and the silence of the in-between months. What helps, what does not.
-
Stopping
Stopping GLP-1: what the evidence says, and how to prepare for it
The STEP-1 extension, the SURMOUNT-4 trial, and what they say about discontinuing semaglutide and tirzepatide. How to think about it with your physician.
-
Body composition
Muscle, bone and GLP-1: the resistance-training conversation
Lean mass loss is real on GLP-1 therapy. The evidence on resistance training, protein intake and bone health, and what a sustainable plan looks like.
-
Micronutrients
GLP-1 and vitamin B12: the silent risk and how to monitor it
Slowed gastric emptying, reduced food intake, and the long timeline of B12 stores. What to ask for, when, and what the supplementation literature says.
-
Comparison
Wegovy vs Mounjaro: what the real-world data shows in 2026
Beyond STEP-1 and SURMOUNT-1: the head-to-head SURMOUNT-5 trial, the real-world evidence on persistence and tolerability, and how the choice is being made today.
-
Patient empowerment
Preparing your next AOM consultation: a 10-minute, evidence-based checklist
What physicians want to know in a 15-minute slot, what you should bring, what red flags to surface first, and how to make the most of the time you have.